{"product_id":"epcoritamab-elisa-kit-dy257038","title":"Epcoritamab ELISA Kit - DY257038","description":"\u003cp\u003eEpcoritamab ELISA Kit\u003c\/p\u003e\n\n\u003cp\u003eSize: 96T\u003c\/p\u003e\n\n\u003cp\u003eCatalogue Number: DY257038-96\u003c\/p\u003e\n\n\u003cp\u003eCitations, Manuals and MSDS Available upon request.\u003c\/p\u003e\n\n\u003cp\u003eStability and Storage: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\n\n\u003cp\u003eDetection Method: Colorimetric\u003c\/p\u003e\n\n\u003cp\u003eSample Type: Plasma, Serum\u003c\/p\u003e\n\n\u003cp\u003eAssay Type: Quantitative\u003c\/p\u003e\n\n\u003cp\u003eSensitivity: 0.156 μg\/ml\u003c\/p\u003e\n\n\u003cp\u003eRange: 0.31-5 μg\/mL\u003c\/p\u003e\n\n\u003cp\u003eRecovery: 80-120%\u003c\/p\u003e\n\n\u003cp\u003eBackground: Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed\/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed\/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.\u003c\/p\u003e\n\n\u003cp\u003eShipping: 2-8 ℃\u003c\/p\u003e\n\n\u003cp\u003eFor Research Use Only.\u003c\/p\u003e","brand":"abinScience","offers":[{"title":"Default Title","offer_id":45353676505267,"sku":"DY257038-96","price":1576.4,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0305\/9482\/6376\/files\/abinscience.png?v=1773676488","url":"https:\/\/afsbio.com\/products\/epcoritamab-elisa-kit-dy257038","provider":"AFSBio Inc.","version":"1.0","type":"link"}